Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxia Ganmao (also known as Huoxia Cold Granules or Huoxia Ganmao Keli) is a Class 1.1 innovative traditional Chinese medicine (TCM) developed by Yiling Pharmaceutical for the treatment of the common cold and gastrointestinal-type colds. It is formulated as a multi-herb granule for oral administration. The formulation is specifically indicated for patients presenting with the TCM syndrome pattern of 'wind-pathogen attacking the exterior with dampness obstructing the middle' (风邪袭表,湿蕴中阻证). It works by releasing the exterior, harmonizing the middle, expelling filth, and resolving dampness to alleviate symptoms such as fever, headache, nasal congestion, nausea, vomiting, diarrhea, and gastrointestinal discomfort. Huoxia Ganmao is currently in Phase III clinical development in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huoxia Ganmao.
Work on Huoxia Ganmao? Claim this page to correct or add information. Claim this page